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Abstract
Background: DICER1 syndrome is a pediatric cancer predisposition condition causing a variety of tumor types in
children and young adults. In this report we studied a family with two relatives presenting a variety of neoplastic
conditions at childhood.
Methods: Germ-line mutation screening of the complete coding region of the DICER1 gene in genomic DNA from
the proband was performed. The presence of somatic DICER1 mutation and further alterations in driver genes was
investigated in genomic DNA obtained from available tumor samples.
Results: A nonsense germ-line mutation in DICER1 causing a truncated protein at the IIIb domain level was
identified segregating within a family including two affected relatives who developed in one case cystic nephroma
and pleuropulmonary blastoma, and rhabdomyosarcoma and multinodular goiter in the other. Additional in trans
DICER1 missense somatic mutations in the IIIb DICER1 domain were found both in the cystic nephroma and in the
rhabdomyosarcoma, suggesting that neoplasms in this family might arise from the unusual two-hit mechanism for
DICER-derived tumorigenesis in which after the presence of a truncated constitutive protein, a neomorphic DICER1
activity is somatically adquired. Additional genetic alterations, such as TP53 mutations, were identified in the
rhabdomyosarcoma.
Conclusions: Besides DICER1 loss of standard activity, oncogenic cooperation of other genes, as mutated TP53, may
involve developing higher grade tumors within this syndrome. Given the broad clinical spectrum that may arise,
genetic counseling and close surveillance must be offered to all family members at risk of DICER1 syndrome.
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Background
Germ-line mutations in DICER1 have been described in the
so-called DICER1 syndrome, a pleiotropic pediatric cancer
predisposition condition causing a variety of tumor types in
children and young adults, including pleuropulmonary
blastoma (PPB), cystic nephroma (CN), rhabdomyosarcoma
(RMS), multinodular goiter, ovarian Sertoli-Leydig cell
tumor and other neoplastic conditions. DICER1 is a multi-
domain protein, containing two endoribonuclease III do-
mains. In the majority of cases, germ-line mutations are
nonsense, frameshift or splice-site mutations leading to pre-
mature truncation of the protein, resulting in loss of RNA-
seIII function [1–3]. RNA processing endoribonucleases are
required for the biogenesis of microRNAs (miRNAs), cleav-
ing precursor miRNAs into mature miRNAs which, in turn,
post-transcriptionally regulate messenger RNA expression
[2]. Disregulation of miRNAs is implicated in several
human diseases, as they participate in many different
biological processes. Thus, mutations in DICER1 have the
potential to affect many biological functions and originate
different phenotypes. In this communication, germ-line and
somatic mutations in DICER1 are reported within a family




Our studied pedigree comprised 8 individuals. All subjects
or their parents/legal guardians gave written informed
consent for genetic research studies and peripheral blood
samples were taken. Available frozen tumor tissue samples
were obtained from HUCA Tumor Bank. Written in-
formed consent for sample banking and research use was
obtained at the time of the surgery.
DNA, RNA and cDNA samples
DNA from peripheral blood and tumor tissues was ex-
tracted using DNAzol (Molecular Research Center, USA),
following manufacturer’s instructions. RNA was obtained
from frozen CN and ERMS frozen tissue samples with Tri-
reagent® (Ambion). cDNA was synthesized with RNA
ImProm-II Reverse Transcriptase (Promega Corporation,
Madison, WI, USA), following manufacturer’s instructions.
Mutational analyses
Individual coding exons of the DICER1 and TP53 gene
including flanking intronic regions were amplified by
PCR. Primer sequences are available on request. Purified
sequence reactions were resolved on a capillary automated
Sanger sequencing (ABIPrism310, Applied Biosystems,
Thermo Fisher Scientific). GenBank reference sequence
accession numbers were NM_177438, NG_016311, and
NP_803187 for DICER1 and NG_017013.2, NM_000546.4
for TP53 gene.
Hot spot mutations in KRAS, NRAS, EGFR, PIK3CA
and BRAF were sought by real-time quantitative allele-
specific PCR amplification using commercial kits (RAS
Mutation Screening Panel, Entrogen, USA; therascreen
EGFR RGQ PCR Kit V2, Qiagen, UK; cobas PIK3CA
Mutation Test, Roche, USA; cobas 4800 BRAF V600
Mutation Test, Roche, USA), following manufacturer’s in-
structions. Deletions or amplifications in PDGRFA, TP53,
CDKN2A, CDK4, RB1, EGFR, PTEN, and MMDM2 genes
and in the chromosomal regions 1p and 19q were
studied by MLPA (Multiplex Ligation-dependent Probe
Amplification) using commercial kits (P0471, P088, and




Index case was a 2-year-old girl presenting a cystic
nephroma at 11 months of age that required surgical re-
section of her left kidney. A computed tomography of
the chest revealed a cystic mass in the left lower lobe ad-
jacent to the diaphragm. At 14 months of age, a left
lower lobectomy was performed and a pathological diag-
nosis of type I PPB was established (Fig. 1a and b).
Germ-line mutational analysis
Considering patient’s tumors nature, genetic mutation
screening of the complete coding region of the DICER1
gene in genomic DNA from proband’s blood was per-
formed. It led to identify a nonsense truncating mutation
affecting Q1783 residue, codified in exon 24 (c.5387C > T;
p.Q1783*). This mutation was found in heterozygosity and
predicted to truncate the protein by the RNaseIIIb domain
of the enzyme. We studied segregation of this germ-line
mutation with diverse pathologies in 7 available relatives
and identified the proband’s mother and grandmother as
carriers of the mutation (Fig. 2). In addition, a 21-year-old
female cousin of the proband who was diagnosed of an
embryonal RMS (Fig. 1c) at age 14 and multinodular goi-
ter at age 20, was also germ-line carrier of the DICER1
mutation. Interestingly, thyroid affection was also reported
in most of the family members, being multinodular goiter
with calcifications the only remarkable pathological pheno-
type present in the proband’s mother and grandmother. Of
those participating in the study, 4 out of 5 affected of thy-
roid alterations carried the p.Q1783* mutation.
Somatic mutation analysis
The presence of an additional somatic mutation in the
remaining DICER1 allele was investigated in genomic
DNA obtained from CN and ERMS available tumor sam-
ples. Tumor tissue from the PPB was not accessible for
molecular studies since the number of tumor cells was
very low (Fig. 1b) and the block tissues were exhausted for
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histological diagnosis. We found a missense heterozygous
c.5425G >A (p.G1809R) mutation in DNA obtained from
CN, whereas ERMS harbored a c.5428G >C (p.D1810H)
substitution, also in heterozygosis (Fig. 2b and c).
Somatic mutational analyses in additional putative
oncogenic driver genes with clinical relevance were stud-
ied. No alterations in KRAS, NRAS, EGFR, PIK3CA, BRAF,
PDGRFA, TP53, CDKN2A, CDK4, RB1, EGFR, PTEN, and
MMDM2 genes were detected in the CN. In contrast, in
genomic DNA from ERMS we found TP53 to carry the
c.404G >A (p.C135Y) mutation in heterozygosity. ERMS
tumor also harbored additional gene alterations: low amp-
lification of EGFR, PDGFRA, and CDK4 genes, and loss of
heterozygosity of CDKN2A and 19q12-19q13.43 chromo-
somal regions.
Mutation allelic configuration
We aimed to investigate if the somatic and germ-line
DICER1 mutations were separate events on different al-
leles. For this purpose, we analyzed cDNA synthesized
from ERMS tumor RNA. Due to the fact that germ-line
c.5387C > T (p.Q1783*) mutation creates an HpyCH4V
restriction site, we designed a PCR amplification and
HpyCH4V digestion assay in which the somatic mutations
would be included in the restriction fragment generated
by the presence of germ-line mutation. Sequencing ana-
lysis of germ-line mutated restriction fragments revealed
that germ-line and somatic mutations lied in trans.
Discussion
In this report we identify germ-line and somatic DICER1
gene mutations in a Caucasian family where two young
females were diagnosed, one with cystic nephroma and
pleuropulmonary blastoma, and the other with embry-
onal rhabdomyosarcoma and multinodular goiter. This
pedigree demonstrates that genetic alteration in the
DICER1 gene can cause a wide clinical spectrum of
carcinomas, in accordance with recent studies [1].
Both affected patients shared the nonsense c.5347C > T
germ-line DICER1 mutation, predicted to truncate the
Fig. 1 Morphologic study of the reported tumors. a. Left nephrectomy from the proband. Top: Gross morphology image of the resected kidney
presenting a thin-wall multicystic parenchyma. Middle: Medium power view of a haematoxylin and eosin staining (HE) showing multiple cysts of
different size. Scarce renal tissue is preserved. Bottom: Higher power view of the cysts surface showing a single layer of flattened/cuboidal cells
with well oriented nuclei, acidophilus cytoplasm, and without atypia. b. Left lower lobectomy from the proband. Top: Gross morphology image
of the resected lobe. An arrow is pointing to the cystic lesion of 12 mm largest size. Middle: At histological level, a unique benign cystic lesion
was identified (HE). Bottom left: A single cubic-cell layer lining the epithelium was observed in most of the cystic lesion. Bottom right: Only very
few and isolated clumps of primitive mesenchymal cells and small clusters of cells with rhabdomyomatous differentiation were found along the
whole tissue sample. c. Histological images of the rhabdomyosarcoma from the proband’s cousin. Top: HE staining showing dense neoplastic cell
proliferation in a solid-storiform pattern. Bottom: Intense pleomorphism is observed, with fusiform-oval cells and common mitotic figures, with
focal anaplastic cells
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protein, and thus likely impairing activity of the DICER1
enzyme [3].
Interestingly, thyroid affection was also reported in
most of the family members. However, we were not able
to establish definitive association of the DICER1
mutation with any specific thyroid disease due to lack of
access to detailed clinical histories or affected tissue
samples from these patients. As goiter is an endemic dis-
ease in Asturias (North of Spain) [4], from where the
family is native, it cannot be discarded the existence of
Fig. 2 a. Pedigree of the studied family. Clinical phenotypes are represented with colors. Individuals screened for DICER1 mutations are indicated
with + or— if the germ-line mutation was present or absent, respectively. The index patient is marked with an arrow. b. Schematic representation of
DICER1 protein structure and corresponding gene exons. Positions of the here identified mutations are indicated. c. Electropherograms corresponding
to the germ-line c.5347C > T (p.Q1783*) and somatic c.5425G > A (p.G1809R); c.5428G> C (p.D1810H) mutations
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further risk factors for thyroid affection within this
pedigree.
We identified additional somatic missense DICER1
mutations in CN and ERMS tumors (p.G1809R and
p.D1810H, respectively), affecting metal ion-binding re-
gions of the protein and thus presumably affecting cata-
lytic activity of RNAseIIIb (but not RNAaseIIIa) domain
[3]. In contrast with the initially proposed theory of hap-
loinsufficiency of this tumor suppressor gene as the
cause underlying DICER1 syndrome [5], our results sup-
port the hypothesis that patients harboring a loss-of-
function germ-line DICER1 mutation acquire a second
somatic hit during tumorigenesis, resulting in a modified
enzyme activity, at the RNAseIIIb level [6]. Loss of RNA-
seIIIb activity of DICER1 protein has been shown to se-
lectively reduce the generation of 5p miRNAs, with no
influence on 3p miRNAs processing, and thus generating
a deregulation of control in gene expression [7, 8]. As we
have established in our samples, since the second somatic
mutation lies in trans, both alleles are compromised. This
need of a compound disruption of DICER1 may explain
the low penetrance of germ-line DICER1 mutations alone.
Given the wide clinical phenotypes observed, add-
itional somatic gene mutations might be involved in the
carcinogenic mechanisms of the syndrome. The malignant
nature of ERMS tumor is underlined by the presence of
additional genomic alterations, especially TP53 mutations.
The TP53 gene c.404G >A mutation (p.C135Y) identified
in ERMS results in the loss of one of the two p53 intramo-
lecular disulfide bonds. Consequently, the protein conform-
ation and subcellular location are altered [9, 10]. Moreover,
it has been proposed that mutant p53 can down-regulate
DICER1 expression, enhancing the metastasic potential of
tumor cells [11]. Therefore, we suggest that, in addition to
DICER1 loss of full activity, oncogenic cooperation of other
genes, such as mutated TP53, may involve developing of
higher grade tumors. ERMS tumor also harbored genomic
alterations in several frequent driver genes.
Conclusions
Given the variety of tumors developed within this family,
and the risk of ovarian cancer (Sertoli-Leydig type) [1, 3, 6]
and thyroid affection in adults, a close surveillance might
be offered to all at risk family members of DICER1 syn-
drome pedigrees.
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